Product Description
Mechanisms of Action: NaR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Axsome
Company Location: NEW YORK NY 10007
Company CEO: Herriot Tabuteau
Additonal Commercial Interests: Pfizer
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Fibromyalgia|Myofascial Pain Syndromes
Phase 1: Healthy Volunteers|Fibromyalgia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2008-006760-10 | P3 |
Terminated |
Fibromyalgia |
2010-08-14 |
|
| A6061054 | P3 |
Withdrawn |
Fibromyalgia|Myofascial Pain Syndromes |
2010-05-01 |
|
| TQT | P1 |
Completed |
Fibromyalgia |
2009-07-01 |
|
| A6061061 | P2 |
Completed |
Fibromyalgia|Myofascial Pain Syndromes |
2009-06-01 |
22% |